Revvity reported first-quarter 2026 results on May 5, with revenue of $711 million, up 7% headline and 3% organic versus $665 million in the prior-year quarter. GAAP EPS from continuing operations was $0.37, against $0.35 a year ago; adjusted EPS was $1.06, against $1.01.
By segment, Life Sciences revenue was $362 million with a 28.7% adjusted operating margin, and Diagnostics revenue was $349 million with a 21.8% adjusted operating margin. Group adjusted operating margin was 23.6%, down from 25.6%, with management citing mix and FX as the dominant drag. Alongside the print, Revvity disclosed a letter of intent signed on April 16 to divest its China Immunodiagnostics business for up to $200 million, with the sale targeted to close in 2027. That unit accounted for roughly 6% of fiscal 2025 revenue. Management framed the exit as a response to persistent policy-induced pricing pressure and structural requirements for localised manufacturing in China. On a pro forma basis excluding that business, the company set 2026 targets of 3-4% organic growth, $2.81-2.84 billion in revenue, an adjusted operating margin near 28.4%, and adjusted EPS of $5.20-5.30. The divestiture is expected to lift organic growth by about 100 basis points and operating margin by about 30 basis points, while trimming EPS by roughly $0.15.
For analytical-instrument buyers, Revvity’s print reinforces a pattern already visible in the Thermo Fisher and Bruker Q1 disclosures: headline revenue holds up, segment margins compress, and vendors are actively pruning lower-quality geographies and product lines rather than chasing volume. The China Immunodiagnostics carve-out is the latest data point on that trend; it does not directly touch the process-analytics tool stack, but it sharpens the comparison with peers still carrying full China exposure in their reagent and consumables lines.